drugset
drugset / Trial / NCT00919958

Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia

NCT00919958 ↗

Phase 1 Completed 15 enrolled Pluristem Ltd.
Non-randomizedFactorialOpen-labelTreatment

Summary

The The purpose of this study is to determine the safety of PLX-PAD single dose, Intra-muscular injection for the treatment of CLI patients.

Timeline

Start
2009-06
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject EMIPLACEL Cell therapy — Intramuscular

Indications

limb ischemia peripheral arterial disease